Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemo + RT + Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
NCT07136519Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Jul 2025
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, omega-3-acid triglycerides in nasopharyngeal carcinoma (NPC), sponsored by The Affiliated Hospital of Guangdong Medical University. Started Jul 2025; status: recruiting.
02
Drugs
toripalimabomega-3-acid triglycerides
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07136519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136519.